MLABNasdaqIndustrial Instruments For Measurement, Display, and ControlFiscal year ends March 31
MESA LABORATORIES INC /CO/
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$123.31+0.83 (+0.67%)
Close on Oct 19, 2026
- Market cap
- $709.87M
- P/E (TTM)
- 145.1
- Dividend yield
- 0.52%
MESA LABORATORIES INC /CO/ revenue by segment
By business segment
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sterilization and Disinfection Control [Member] | $100.66M | $101.57M | $97.18M | $95.77M | $95.87M | $93.42M | $91.45M | $87.28M | $82.15M | $75.12M | $68.93M | $65.88M | 40.3% | +5.0% |
| Calibration Solutions [Member] | $54.49M | $53.55M | $53.25M | $53.61M | $52.30M | $51.75M | $51.31M | $49.04M | $48.10M | $47.76M | $47.57M | $46.18M | 21.8% | +4.2% |
| Biopharmaceutical Development [Member] | $49.20M | $48.63M | $52.40M | $50.26M | $48.21M | $48.73M | $48.30M | $45.49M | $42.83M | $40.71M | $41.13M | $43.35M | 19.7% | +2.1% |
| Clinical Genomics [Member] | $45.38M | $45.39M | $44.72M | $45.62M | $45.97M | $47.08M | $46.69M | $46.57M | $50.62M | $52.59M | $55.24M | $58.28M | 18.2% | -1.3% |
By product or service
By region
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $118.99M | $116.90M | $118.04M | $118.62M | $117.40M | $116.62M | $112.61M | $107.72M | $106.72M | $106.40M | $107.73M | $110.78M | 47.6% | +1.4% |
| Other [Member] | $110.28M | $111.79M | $108.07M | $104.53M | $100.77M | $99.05M | $98.52M | $95.42M | $91.61M | $84.86M | $79.42M | $74.65M | 44.2% | +9.4% |
| China | $20.46M | $20.45M | $21.43M | $22.11M | $24.18M | $25.31M | $26.62M | $25.24M | $25.38M | $24.93M | $25.72M | $28.26M | 8.2% | -15.4% |
From the segment and revenue-disaggregation notes of Mesa Laboratories's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.